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Osteonecrosis (ON) is a critical complication in the treatment of childhood leukemia and lymphoma. It particularly aﬀects
survivors of acute lymphoblastic leukemia and non-Hodgkin lymphoma reﬂecting the cumulative exposure to glucocorticosteroid
therapy. ON is often multiarticular and bilateral, specially aﬀecting weight-bearing joints. A conventional approach suggests a
surgical intervention even if pharmacological options have also recently been investigated. We reported two cases of long time
steroid-treated patients who underwent Bone Marrow Transplantation (BMT) for hematological disease. Both patients developed
femoral head osteonecrosis (ON) that was diagnosed by magnetic resonance imaging (MRI) and the ON was also accompanied
with pain and a limp. Despite of the conventional strategies of therapy, we successfully started a short-term treatment with
bisphosphonates in order to decrease the pain and the risk of fracture.
1.Introduction
Osteonecrosis (ON) is recognised as a complication of the
treatment of hematologic malignancies in children and ado-
lescents. The hips and the knees are the joints aﬀected more
frequently but involvement of the ankles is also described [1,
2]. The majority of patients present pain, limping, articular
collapse, arthritis, and limitation of movement but in some
cases it is completely asymptomatic. Spontaneous resolution
can occur in these patients, especially in the case of small
lesions [3] even if a majority of them have a progressive dis-
order,endinginthecollapseoftheaﬀectedjoints.TheHarris
hip score [4], evaluating pain, functional capacity, range of
motion and deformity, is very useful to asses morbidity.
Published reports and retrospective analysis are often
limited to symptomatic patients. For these reasons, the true
prevalence is probably underestimated [5].
In the last few years, the number of patient survivors
after BMT has increased and the long follow-up period
has made it possible to observe some late eﬀects. ON is
increasingly reported as a severe disabling complication, as
well as osteoporosis, especially in patients receiving steroids
for cancer treatment or as prophylaxis/treatment for graft-
versus-hostdisease (GVHD) [6]. An early diagnosis of ON
is essential in order to prevent its progression and MRI
is considered the gold standard for early diagnosis and
followup [7].
Several risk factors for ON have been identiﬁed in
the LLA context. It seems that ON is more common in
whites and in adolescents than in blacks [8–10] or children
especially under 13 years old with a high BMI [9, 10]. The
maturing bone of the adolescents may be more susceptible to
the development of ON.
T h ep a t h o g e n e s i si sc o m p l e xa n di n c l u d e ss u p p r e s s i o n
of bone formation, expansion of the intramedullary lipocyte
compartment and a direct eﬀect on the nutrient arteries. The
ChildrenCancerGroup(CCG)1882studyalsodemonstrates
that the incidence of ON correlates with the amount of2 Case Reports in Medicine
Figure 1: Moderate bilateral joint eﬀusion and fat-like aspects of
osteonecrosis involving the weight bearing portion of the femoral
heads.Inthelefthipwherethearticularsurfaceispartiallyﬂattened.
Bone marrow oedema is also present bilaterally, around the femoral
capital necrosis.
dexamethasone received [10]. Corticosteroids are integral
to the management of childhood acute lymphoblastic
leukaemia (ALL) [11]. Improvements in event-free survival
(EFS) have been achieved with the addition of dexam-
ethasone to standard prednisone-based therapies [12]. This
therapy has been associated with a dramatic increase in
the occurrence of ON and may be directly linked with
dexamethasone, which seems to be stronger than prednisone
in both its antileukemic and toxic eﬀects [11, 13].
Wedescribedthecasesoftwopediatricpatientswhowere
on long-term steroid treatment before BMT for hematologic
disease and for acute or chronic GVHD. They presented
ON of the femoral head and osteoporosis after BMT.
Bisphosphonates (Alendronate) were used to treat them for
about a period of 12 months, after parental consent, and the
therapy ended when the pain and limping had stopped for a
signiﬁcant period of time.
2.Case 1
The ﬁrst patient, now 20 years old, had originally been
diagnosed with anaplastic Large Cell Lymphoma when
he was 12 and received corticosteroid therapy according
to the AIEOP NHL 92 protocol, Dexamethasone (DXM)
448mg/m2 until relapse and DXM 420mg/m2 from the
ﬁrst relapse to the pretransplantation conditioning regimen.
After 4 relapses, he underwent matched unrelated donor
(MUD) transplantation. The conditioning regimen was TBI
(1200cGy), Thiotepa (TT), Ciclophosphamide (CPM), and
Antithymocyte globulin (ATG).
A six-month treatment with corticosteroids (Methyl-
prednisolone 8975mg/m2, Prednisone 10500mg/m2,a n d
Hydrocortisone 2710mg/m2)w a su s e df o rg r a d eI Va c u t e
and severe chronic GVHD of gut, skin, and lungs. Eight
months after BMT, while still under corticosteroid therapy,
he developed a limp and severe pain in the left hip. An
MRI was performed (Figure 1)a n dr e v e a l e dam o d e r a t e
joint eﬀusion, as well as fat-like aspects of osteonecrosis
Figure 2: Bilateral joint eﬀusion and bone marrow oedema are
disappeared. The right femoral head shows a regular articular
surface but with aspects of midollary sclerosis. Partial aspect of
fragmentation on the left femoral capital necrosis.
involving the weight bearing portion of the femoral heads
particularly extruded in the left hip where the articular
surface was partially ﬂattened. Bone marrow oedema was
also present bilaterally around the right femoral capital
necrosis (Figure 1). A DEXA was performed, which showed
osteoporosis. The blood test indicated that related bony
tissue turnover was normal.
Orthopaedic suggestions were to limit weight bearing,
functional discharge, and the rest of hip joints. Since the
pain persisted, a treatment with Alendronate was added
to the conventional therapy when he was 13 years old.
This therapy was started 6 months after ON had been
diagnosed, at the dosage of 10mg a day, and ended 11
months later, without any side eﬀects. One month after the
beginning of bisphosphonates therapy, the patient reported
improvement of the limp together with a considerable
decrease of pain and a gradual recovery of normal motor
activity. An MRI, performednine months fromthe diagnosis
of ON, showed a resolution of the bilateral joint eﬀusion
and bone marrow oedema. The right femoral head showed
a regular articular surface but with aspects of midollary
sclerosis. The left femoral capital necrosis presented a partial
aspect of fragmentation (Figure 2).
At the last followup, 7 years from the initial symptoms,
the patient reported the absence of pain as well as fully
functioning joint motility.
3.Case 2
The second patient is an 18-year-old girl who had a bone
marrow relapse for ALL at 10 and had undergone an MUD
BMT.PretransplantationconditioningregimenincludedTBI
1200cGy, TT, CPM, and ATG. Before BMT, corticosteroids
were administered according to induction and reinduc-
tion therapy of AIEOP protocol 9502 (Methylprednisolone
211mg/m2, Prednisone 150mg/m2, and DXM 360mg/m2).
In addition, Prednisone was administered for one month
(total dose 1950mg/m2) to prevent an acute GVHD. AfterCase Reports in Medicine 3
Figure 3: Flattened right femoral head, joint eﬀusion, enlarged
physes, bone marrow oedema of the femoral neck, and minimal
sclerotic changes of the articular surface. There is a remarkable
increase of the signal on T1W sequences only in the deep portion
of the femoral head.
6 months from the bone marrow infusion, she developed a
limp and pain on the weight bearing joint in the right hip.
MRI examination showed a ﬂattened right femoral head,
joint eﬀusion, enlarged physes, bone marrow oedema of the
femoral neck, and minimal sclerotic changes of the articular
surface. After Gadolinium IV, there was a remarkable
increase of the signal on T1W sequences only in the deep
portion of the femoral head (Figure 3).
A DEXA was also performed, which showed diminished
bone-density, conﬁrming the diagnosis of osteoporosis. The
blood test indicated that related bony tissue turnover was
normal.
Pressure was relived from the aﬀected joint, and the
patient underwent physiotherapy. Six months after the
diagnosis of ON, when she was 11 years old, she started a
therapy with Alendronate, 5mg a day for two weeks and
then we increase the dose to 10mg a day. Two months
later, the patient reported a signiﬁcant decrease of pain.
Bisphosphonates therapy lasted for 12 months, without any
side eﬀect. The last MRI, performed 30 months from initial
symptoms, showed a better boundary line of the necrosis of
the capital of the femur with a fat-like aspect, good remod-
ellingofthefemoralhead,morphologic normalization ofthe
physes, and only minimal ﬂattening of the articular surface
(Figure 4).Bone-densitydensitometryresultsalsoimproved.
Now 6.5 years since the initial symptoms, she has completely
recovered and is even capable of mild sport activities.
4. Discussion
Skeletal morbidity, characterized by bone pain, osteonecro-
sis, fractures, loss of mobility, bone deformation, or osteope-
nia, is frequently encountered in patients aﬀected by ALL.
Orthopaedic management of symptomatic ON varied. This
morbidity can cause immobility and consequently a sub-
stantial reduction in the quality of life and may require
surgical interventions such as core decompression [14],
arthrodesis, and joint replacement. Furthermore, resurfac-
ing hemiarthroplasties were recently performed to treat
advanced osteonecrosis in young adult patients [15]. Allevia-
tion of weight from the aﬀected joints (employing crutches
or wheelchair) for a certain period together with physical
Figure 4: Boundary line of the necrosis of the capital of the femur
with a fat-like aspect, good remodelling of the femoral head, and
morphologic normalization of the physes are shown in this follow
up MRI.
therapyisusuallyrecommendedformanypatients.Thereare
some concerns [16] regarding using surgical interventions in
growing open physes, although the conventional approach
is still surgery. Nonsurgical intervention includes external
electrical stimulation/capacitance coupling [17, 18] and the
use of hyperbaric oxygen [19].
We still have little experience concerning the pharma-
cological treatment of ON but recently some studies [20–
23] have shown that Alendronate oﬀers an added advantage
in children and adolescents with either ALL or a malignant
lymphoma with ON.
Bisphosphonates are very important inhibitors of osteo-
clastic bone resorption in vivo [24] and are used in diseases
such as osteoporosis, hypercalcemia of malignancy, Paget’s
disease of bone, and osteolytic bone disease [25–27]. How-
ever, up to now there had not been any indications for the
use of these drugs in the treatment of ON. They are safely
used in treating childhood hypercalcemia, secondary to
acute lymphocytic leukaemia [28, 29]. The administration of
bisphosphonates produced normocalcemia in these patients
apparently without any signiﬁcant side eﬀects. ON of the jaw
or oesophageal cancer after bisphosphonates infusion rep-
resents well-known complications in adult cancer patients
[30, 31] but in children these complications have not been
reported. Long-term potential eﬀects from their use during
the active phase of growth still remain unknown.
Goldbloom and collaborators have also used bisphos-
phonates to treat vertebral fractures of two children aﬀected
by acute lymphoblastic leukemia (ALL) [32]. The authors
report the successful use of pamidronate on both patients
whohadoriginallyhadpainandlowbonemineraldensity.In
addition to standard chemotherapy, pamidronate (1mg/kg,
IV) was given bimonthly. Initial rapid symptom relief and
gradual improvement of bone mineral density were demon-
strated in both patients. It remains to be demonstrated
whether osteonecrotic collapse can also be prevented with
the use of these medicaments. In fact, the inhibition of
osteoclast activity by the use of bisphosphonates could
possibly lead to an increase in bone mass and strength in
these sites. Moreover, in orthopedic conditions it is often4 Case Reports in Medicine
possible to apply the drug locally. This will give a much
higher local oncentration because of the pharmacokinetics
eﬀects of the bisphosphonates which remain in the site for
a long time. When we had originally decided to treat our
patients with Alendronate, there was no information on this
drug concerning its use in relation to ON. Therefore, in our
patients the lack of symptoms and the absence of fractures
after 7 years seem to be encouraging.
These promising approaches including the use of these
a n t i r e s o r p t i v ed r u g sa sw e l la ss t r a t e g i e ss u c ha st h ee m p l o y -
ment of lipid lowering agents are being currently explored
[33]. It is very diﬃcult to prevent ON in children but
high-risk groups of patients are identiﬁable and have to be
monitored; clinical and radiological examinations have to
be conducted as well as measures of functional assessment
whichwouldallhelpthepatientattainabetterqualityoflife.
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